头孢克洛在终末期肾病患者及血液透析期间的药代动力学。
Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis.
作者信息
Berman S J, Boughton W H, Sugihara J G, Wong E G, Sato M M, Siemsen A W
出版信息
Antimicrob Agents Chemother. 1978 Sep;14(3):281-3. doi: 10.1128/AAC.14.3.281.
Abstract
A single 1.0-g dose of cefaclor administered to patients with stable end stage renal disease whose creatinine clearances were <5 ml/min produced a mean peak serum concentration of 48.3 +/- 19.8 mug/ml. The half-life was 2.3 +/- 0.3 h. Hemodialysis shortened the half-life of a similar dose to 1.6 +/- 0.3 h. Approximately one-third (340 mg) of the administered drug was recovered in the dialysate. Multiple doses of 500 mg every 6 h between hemodialysis sessions produced effective serum concentrations and no bioassay evidence of drug accumulation.
摘要
给肌酐清除率<5ml/分钟的稳定终末期肾病患者单次服用1.0g头孢克洛，血清平均峰浓度为48.3±19.8μg/ml。半衰期为2.3±0.3小时。血液透析将相似剂量的半衰期缩短至1.6±0.3小时。约三分之一（340mg）的给药剂量可在透析液中回收。在血液透析期间每6小时多次给予500mg药物可产生有效的血清浓度，且生物测定未发现药物蓄积的证据。
相似文献
1
Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis.头孢克洛在终末期肾病患者及血液透析期间的药代动力学。
Antimicrob Agents Chemother. 1978 Sep;14(3):281-3. doi: 10.1128/AAC.14.3.281.
2
Pharmacokinetics of cefaclor and cephalexin: dosage nomograms for impaired renal function.头孢克洛和头孢氨苄的药代动力学：肾功能受损时的剂量列线图
Antimicrob Agents Chemother. 1978 Aug;14(2):172-7. doi: 10.1128/AAC.14.2.172.
3
Pharmacokinetics of cefamandole in patients with renal impairment.头孢孟多在肾功能损害患者中的药代动力学。
Antimicrob Agents Chemother. 1979 Feb;15(2):161-4. doi: 10.1128/AAC.15.2.161.
4
Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis.头孢克洛在肾衰竭中的药代动力学：多次给药及血液透析的影响
Antimicrob Agents Chemother. 1982 Feb;21(2):278-81. doi: 10.1128/AAC.21.2.278.
5
Pharmacology of cefaclor in normal volunteers and patients with renal failure.头孢克洛在正常志愿者和肾衰竭患者中的药理学。
Antimicrob Agents Chemother. 1978 Jun;13(6):951-4. doi: 10.1128/AAC.13.6.951.
6
Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.头孢雷特在接受血液透析的终末期肾病患者中的药代动力学。
Antimicrob Agents Chemother. 1980 Feb;17(2):251-3. doi: 10.1128/AAC.17.2.251.
7
Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function.头孢替坦在正常受试者及肾功能受损患者中的药代动力学。
Antimicrob Agents Chemother. 1983 Jan;23(1):31-5. doi: 10.1128/AAC.23.1.31.
8
The pharmacology of cefamandole in patients with reduced renal function.头孢孟多在肾功能减退患者中的药理学。
Scand J Infect Dis Suppl. 1980;suppl 25:45-8.
9
Moxalactam pharmacokinetics during hemodialysis.血液透析期间的头孢氧哌唑药代动力学。
Antimicrob Agents Chemother. 1981 Apr;19(4):575-7. doi: 10.1128/AAC.19.4.575.
10
Pharmacokinetics of cefamandole in patients undergoing hemodialysis and peritoneal dialysis.头孢孟多在接受血液透析和腹膜透析患者中的药代动力学。
Antimicrob Agents Chemother. 1976 Sep;10(3):457-61. doi: 10.1128/AAC.10.3.457.
引用本文的文献
1
Pharmacokinetic study of an oral cephalosporin, cefdinir, in hemodialysis patients.口服头孢菌素头孢地尼在血液透析患者中的药代动力学研究。
Antimicrob Agents Chemother. 1998 Jul;42(7):1718-21. doi: 10.1128/AAC.42.7.1718.
2
Pharmacokinetics of ceforanide in patients with end stage renal disease on hemodialysis.头孢雷特在接受血液透析的终末期肾病患者中的药代动力学。
Antimicrob Agents Chemother. 1980 Feb;17(2):251-3. doi: 10.1128/AAC.17.2.251.
3
Cefaclor pharmacokinetic parameters: serum concentrations determined by a new high-performance liquid chromatographic technique.头孢克洛的药代动力学参数：采用一种新型高效液相色谱技术测定的血清浓度。
Antimicrob Agents Chemother. 1982 Jan;21(1):170-2. doi: 10.1128/AAC.21.1.170.
4
Elimination of cefroxadine (CGP-9000) from patients undergoing dialysis.接受透析患者体内头孢沙定（CGP - 9000）的清除情况。
Eur J Clin Pharmacol. 1983;24(1):109-12. doi: 10.1007/BF00613936.
5
Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.接受血液透析患者的药物治疗。临床药代动力学考量
Clin Pharmacokinet. 1984 Jan-Feb;9(1):42-66. doi: 10.2165/00003088-198409010-00003.
6
Clinical pharmacokinetics of antibiotics in patients with impaired renal function.肾功能受损患者抗生素的临床药代动力学
Clin Pharmacokinet. 1992 Mar;22(3):169-210. doi: 10.2165/00003088-199222030-00002.
本文引用的文献
1
Cephalexin: absorption and excretion as related to renal function and hemodialysis.头孢氨苄：与肾功能和血液透析相关的吸收和排泄。
Infect Immun. 1971 Apr;3(4):540-3. doi: 10.1128/iai.3.4.540-543.1971.
2
Cephalexin in patients with renal disease.
N Engl J Med. 1970 Oct 1;283(14):720-3. doi: 10.1056/NEJM197010012831402.
3
Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients.口服头孢氨苄和氨苄西林：尿毒症患者的抗菌活性、尿液中的回收率及血液中的持续时间
Ann Intern Med. 1970 Mar;72(3):349-56. doi: 10.7326/0003-4819-72-3-349.
4
Cephalexin therapy as related to renal function.与肾功能相关的头孢氨苄治疗
Am J Med Sci. 1970 Feb;259(2):133-42. doi: 10.1097/00000441-197002000-00007.
5
In vitro studies with cefaclor, a new oral cephalosporin.使用新型口服头孢菌素头孢克洛进行的体外研究。
Antimicrob Agents Chemother. 1977 Oct;12(4):490-7. doi: 10.1128/AAC.12.4.490.
6
In vitro activity of cefaclor, a new orally administered cephalosporin antibiotic.新型口服头孢菌素抗生素头孢克洛的体外活性
Antimicrob Agents Chemother. 1977 Sep;12(3):442-3. doi: 10.1128/AAC.12.3.442.
7
Comparison of in vitro activity of cephalexin, cephradine, and cefaclor.头孢氨苄、头孢拉定和头孢克洛的体外活性比较。
Antimicrob Agents Chemother. 1977 Mar;11(3):470-4. doi: 10.1128/AAC.11.3.470.
8
Stability and blood level determinations of cefaclor, a new oral cephalosporin antibiotic.新型口服头孢菌素抗生素头孢克洛的稳定性及血药浓度测定
Antimicrob Agents Chemother. 1978 Jan;13(1):49-52. doi: 10.1128/AAC.13.1.49.
Zotero 插件